Translational research concerning diagnosis, management, and treatment in cardiovascular disease using vasoactive peptide
Project/Area Number |
20590837
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Circulatory organs internal medicine
|
Research Institution | Dokkyo Medical University |
Principal Investigator |
NISHIKIMI Toshio Dokkyo Medical University, 医学研究科, 准教授 (80291946)
|
Co-Investigator(Renkei-kenkyūsha) |
MINAMINO Naoto 国立循環器病センター, 研究所や栗部, 部長 (50124839)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 臨床心血管病態学 / ナトリウム利尿ペプチド / 心不全 / BNP / ANP / アドレノメデュリン / 脂肪細胞 / Rho-kinase阻害薬 / 腎疾患 / 脳性ナトリウム利尿ペプチド / 分子型 / 賢線維化 / Rho-Kinase阻害薬 / 脂肪組織. / N-terminal proBNP / 糖鎖修飾 / 心房性ナトリウム利尿ペプチド / ナトリウム利尿ペプチド受容体A / cAMP / 脂肪分解作用 / CRLR / RAMPs / 糖取り込み作用 |
Research Abstract |
We investigated the pathophysiological significance of B-type natriuretic peptide (BNP), adrenomedullin, and Rho-kinsae inhibitor. We found that current BNP assay kit measures not only BNP-32, but also proBNP-108 and that measurement of both molecular forms provides more useful information in heart failure. We showed that AM mRNA is highly expressed in adipose tissue and that AM plays a role in lipid and glucose metabolism. Furthermore, we showed that Rho-kinase is activated in the kidney in renal disease and that Rho-kinase inhibitor is effective in treatment for various renal disease models via many mechanisms including inhibition of oxidative stress, inflammation, collagen production, etc.
|
Report
(4 results)
Research Products
(59 results)